Pediatric phase i trial design using maximum target inhibition as the primary endpoint

Holly Meany, Frank M. Balis, Alberta Aikin, Patricia Whitcomb, Robert F. Murphy, Seth M. Steinberg, Brigitte C. Widemann, Elizabeth Fox

Research output: Contribution to journalArticle

Abstract

The extent to which a drug inhibits a target responsible for a therapeutic effect is a more rational primary endpoint for dose-finding studies of more selective anticancer drugs than the conventional endpoint of dose-limiting toxicity (DLT) used for cytotoxic agents. An adaptive phase I trial design incorporating maximum target inhibition as the primary endpoint was developed to define the optimal dose of talabostat, a dipeptidyl peptidase (DPP) inhibitor, in children with relapsed or refractory solid tumors. The relationship between dose and effect (percent inhibition of serum DPP-4) was assessed using a maximum effect model. Maximum target inhibition was defined as greater than 90% DPP-4 inhibition in five or more of six patients 24 hours post-dose. If DLT was to occur, the trial would adapt to a traditional phase I design with a more conservative dose escalation. At the 600 μg/m2 dose level, serum DPP-4 inhibition at 24 hours was 85%. No talabostat-related DLT occurred. The maximum effect model predicted that 1200 μg/m2 of talabostat would maximally inhibit DPP-4. This adaptive trial design appears to be feasible, safe, and efficient and warrants further evaluation for development of molecularly targeted agents.

Original languageEnglish (US)
Pages (from-to)909-912
Number of pages4
JournalJournal of the National Cancer Institute
Volume102
Issue number12
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Dipeptidyl Peptidase 4
Pediatrics
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Cytotoxins
Therapeutic Uses
Protease Inhibitors
Serum
Pharmaceutical Preparations
talabostat
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meany, H., Balis, F. M., Aikin, A., Whitcomb, P., Murphy, R. F., Steinberg, S. M., ... Fox, E. (2010). Pediatric phase i trial design using maximum target inhibition as the primary endpoint. Journal of the National Cancer Institute, 102(12), 909-912. https://doi.org/10.1093/jnci/djq174

Pediatric phase i trial design using maximum target inhibition as the primary endpoint. / Meany, Holly; Balis, Frank M.; Aikin, Alberta; Whitcomb, Patricia; Murphy, Robert F.; Steinberg, Seth M.; Widemann, Brigitte C.; Fox, Elizabeth.

In: Journal of the National Cancer Institute, Vol. 102, No. 12, 06.2010, p. 909-912.

Research output: Contribution to journalArticle

Meany, H, Balis, FM, Aikin, A, Whitcomb, P, Murphy, RF, Steinberg, SM, Widemann, BC & Fox, E 2010, 'Pediatric phase i trial design using maximum target inhibition as the primary endpoint', Journal of the National Cancer Institute, vol. 102, no. 12, pp. 909-912. https://doi.org/10.1093/jnci/djq174
Meany, Holly ; Balis, Frank M. ; Aikin, Alberta ; Whitcomb, Patricia ; Murphy, Robert F. ; Steinberg, Seth M. ; Widemann, Brigitte C. ; Fox, Elizabeth. / Pediatric phase i trial design using maximum target inhibition as the primary endpoint. In: Journal of the National Cancer Institute. 2010 ; Vol. 102, No. 12. pp. 909-912.
@article{997cf3bca8df44fa9b1f39236fba122d,
title = "Pediatric phase i trial design using maximum target inhibition as the primary endpoint",
abstract = "The extent to which a drug inhibits a target responsible for a therapeutic effect is a more rational primary endpoint for dose-finding studies of more selective anticancer drugs than the conventional endpoint of dose-limiting toxicity (DLT) used for cytotoxic agents. An adaptive phase I trial design incorporating maximum target inhibition as the primary endpoint was developed to define the optimal dose of talabostat, a dipeptidyl peptidase (DPP) inhibitor, in children with relapsed or refractory solid tumors. The relationship between dose and effect (percent inhibition of serum DPP-4) was assessed using a maximum effect model. Maximum target inhibition was defined as greater than 90{\%} DPP-4 inhibition in five or more of six patients 24 hours post-dose. If DLT was to occur, the trial would adapt to a traditional phase I design with a more conservative dose escalation. At the 600 μg/m2 dose level, serum DPP-4 inhibition at 24 hours was 85{\%}. No talabostat-related DLT occurred. The maximum effect model predicted that 1200 μg/m2 of talabostat would maximally inhibit DPP-4. This adaptive trial design appears to be feasible, safe, and efficient and warrants further evaluation for development of molecularly targeted agents.",
author = "Holly Meany and Balis, {Frank M.} and Alberta Aikin and Patricia Whitcomb and Murphy, {Robert F.} and Steinberg, {Seth M.} and Widemann, {Brigitte C.} and Elizabeth Fox",
year = "2010",
month = "6",
doi = "10.1093/jnci/djq174",
language = "English (US)",
volume = "102",
pages = "909--912",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Pediatric phase i trial design using maximum target inhibition as the primary endpoint

AU - Meany, Holly

AU - Balis, Frank M.

AU - Aikin, Alberta

AU - Whitcomb, Patricia

AU - Murphy, Robert F.

AU - Steinberg, Seth M.

AU - Widemann, Brigitte C.

AU - Fox, Elizabeth

PY - 2010/6

Y1 - 2010/6

N2 - The extent to which a drug inhibits a target responsible for a therapeutic effect is a more rational primary endpoint for dose-finding studies of more selective anticancer drugs than the conventional endpoint of dose-limiting toxicity (DLT) used for cytotoxic agents. An adaptive phase I trial design incorporating maximum target inhibition as the primary endpoint was developed to define the optimal dose of talabostat, a dipeptidyl peptidase (DPP) inhibitor, in children with relapsed or refractory solid tumors. The relationship between dose and effect (percent inhibition of serum DPP-4) was assessed using a maximum effect model. Maximum target inhibition was defined as greater than 90% DPP-4 inhibition in five or more of six patients 24 hours post-dose. If DLT was to occur, the trial would adapt to a traditional phase I design with a more conservative dose escalation. At the 600 μg/m2 dose level, serum DPP-4 inhibition at 24 hours was 85%. No talabostat-related DLT occurred. The maximum effect model predicted that 1200 μg/m2 of talabostat would maximally inhibit DPP-4. This adaptive trial design appears to be feasible, safe, and efficient and warrants further evaluation for development of molecularly targeted agents.

AB - The extent to which a drug inhibits a target responsible for a therapeutic effect is a more rational primary endpoint for dose-finding studies of more selective anticancer drugs than the conventional endpoint of dose-limiting toxicity (DLT) used for cytotoxic agents. An adaptive phase I trial design incorporating maximum target inhibition as the primary endpoint was developed to define the optimal dose of talabostat, a dipeptidyl peptidase (DPP) inhibitor, in children with relapsed or refractory solid tumors. The relationship between dose and effect (percent inhibition of serum DPP-4) was assessed using a maximum effect model. Maximum target inhibition was defined as greater than 90% DPP-4 inhibition in five or more of six patients 24 hours post-dose. If DLT was to occur, the trial would adapt to a traditional phase I design with a more conservative dose escalation. At the 600 μg/m2 dose level, serum DPP-4 inhibition at 24 hours was 85%. No talabostat-related DLT occurred. The maximum effect model predicted that 1200 μg/m2 of talabostat would maximally inhibit DPP-4. This adaptive trial design appears to be feasible, safe, and efficient and warrants further evaluation for development of molecularly targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=77953699935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953699935&partnerID=8YFLogxK

U2 - 10.1093/jnci/djq174

DO - 10.1093/jnci/djq174

M3 - Article

C2 - 20460632

AN - SCOPUS:77953699935

VL - 102

SP - 909

EP - 912

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -